What is the Riociguat?

Riociguat is , while it's Molecular Formula is C 20 H 19 FN 8 O 2 . Riociguat is used in the treatment for pulmonary hypertension.

What is the CAS number for Riociguat?

The CAS number of Riociguat is 625115-55-1.

What is Riociguat (625115-55-1) used for?

In September 2013, Health Canada approved riociguat (also referred to as BAY 63-2521), for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and for the treatment of adults with pulmonary arterial hypertension (PAH). Riociguat has a dual mode of action and works by (a) sensitizing sGC to the body’s NO by stabilizing NO–sGC binding and (b) an NO-independent, direct stimulation of sGC via a different binding site. This process restores the NO–sGC–cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation.Headache, dizziness, dyspepsia/gastritis, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation were the most common adverse events ( 3%) observed during riociguat clinical trials. Riociguat comes with a black box warning for embryo-fetal toxicity.

What is the Riociguat?

Riociguat is , while it's Molecular Formula is C 20 H 19 FN 8 O 2 . Riociguat is used in the treatment for pulmonary hypertension.

What is the CAS number for Riociguat?

The CAS number of Riociguat is 625115-55-1.

What is Riociguat (625115-55-1) used for?

In September 2013, Health Canada approved riociguat (also referred to as BAY 63-2521), for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and for the treatment of adults with pulmonary arterial hypertension (PAH). Riociguat has a dual mode of action and works by (a) sensitizing sGC to the body’s NO by stabilizing NO–sGC binding and (b) an NO-independent, direct stimulation of sGC via a different binding site. This process restores the NO–sGC–cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation.Headache, dizziness, dyspepsia/gastritis, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation were the most common adverse events ( 3%) observed during riociguat clinical trials. Riociguat comes with a black box warning for embryo-fetal toxicity.

Product Class

625115-55-1

Product Name：Riociguat
Molecular Formula：C₂₀H₁₉FN₈O₂
Purity：99%
Molecular Weight：422.422

Inquiry

Product Details:

CasNo： 625115-55-1

Molecular Formula： C₂₀H₁₉FN₈O₂

Buy High Grade Riociguat,Top Purity 625115-55-1 Best Price

Molecular Formula:C₂₀H₁₉FN₈O₂
Molecular Weight:422.422
Boiling Point:567.202 °C at 760 mmHg
PKA:1.51±0.50(Predicted)
Flash Point:296.833 °C
PSA：138.80000
Density:1.513 g/cm³
LogP:2.95400

Riociguat(Cas 625115-55-1) Usage

Description

Riociguat is a medication used to treat adults with two forms of pulmonary hypertension: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). It is sold under the brand name Adempas and is manufactured by Bayer.

Uses

The primary indication for riociguat is in the treatment of inoperable CTEPH or persistent/recurrent CTEPH after pulmonary endarterectomy. Additionally, it is approved for the treatment of PAH in adults. Riociguat is classified as a first-in-class soluble guanylate cyclase stimulator. It acts as a stimulator of cyclic guanosine monophosphate (cGMP) synthesis rather than as an inhibitor of cGMP metabolism. This stimulation of soluble guanylate cyclase leads to increased levels of cGMP, resulting in various effects.

625115-55-1 Relevant articles

Riociguat for the treatment of pulmonary hypertension

Ralph T Schermuly,Wiebke Janssen,Norbert Weissmann,Johannes-Peter Stasch,Friedrich Grimminger &Hossein Ardeschir Ghofrani

Expert Opinion on Investigational Drugs Volume 20, 2011 - Issue 4

This review will help readers understand the mechanism of action of the soluble guanylate cyclase (sGC) stimulator riociguat (BAY 63-2521) and will provide a comprehensive summary regarding efficacy and safety of this drug in the management of PH. The most relevant publications up to December 2010 were used as sources for this review.

PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL(METHYL)CARBAMATE AND ITS POLYMORPHS THEREOF

-

Page/Page column 15, (2018/06/12)

The present invention relates to an impr...

625115-55-1 Process route

: 1702271-98-4
2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine

: 79-22-1
methyl chloroformate

: 625115-55-1
Riociguat

Conditions

Conditions	Yield
2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine; methyl chloroformate; In isopropyl alcohol; at 40 ℃; for 5h; With triethylamine; In methanol; at 45 ℃; for 1h; Temperature;	89%
With triethylamine; In dimethyl sulfoxide; at 80 ℃; for 3h; Reagent/catalyst; Temperature;	85%
With pyridine; In N,N-dimethyl-formamide; at 0 - 5 ℃; for 0.5h; Temperature;	60%
2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine; With sodium carbonate; In tetrahydrofuran; water; at 0 - 5 ℃; for 0.333333h; methyl chloroformate; In tetrahydrofuran; water; at 0 - 15 ℃; for 4h;	5 g

: 6642-30-4
methyl N-methylcarbamate

: 2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-iodopyrimidine-4,6-diamine

: 625115-55-1
Riociguat

Conditions

Conditions	Yield
With triethylamine; In N,N-dimethyl-formamide; at 20 ℃; for 3h;	90%

625115-55-1 Upstream products

74-88-4
methyl iodide
428854-24-4
2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6- triamine
428854-23-3
C₂₃H₁₈FN₉
1702271-98-4
2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine